Form 8-K - Current report:
SEC Accession No. 0001628280-23-006335
Filing Date
2023-03-03
Accepted
2023-03-03 17:14:05
Documents
13
Period of Report
2023-02-27
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bvs-20230227.htm   iXBRL 8-K 41884
2 EX-99.1 exhibit991bvscartihealprof.htm EX-99.1 373421
  Complete submission text file 0001628280-23-006335.txt   592155

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bvs-20230227.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bvs-20230227_lab.xml EX-101.LAB 25848
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bvs-20230227_pre.xml EX-101.PRE 13582
7 EXTRACTED XBRL INSTANCE DOCUMENT bvs-20230227_htm.xml XML 11439
Mailing Address 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703
Business Address 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 (919) 474-6700
Bioventus Inc. (Filer) CIK: 0001665988 (see all company filings)

EIN.: 810980861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37844 | Film No.: 23705705
SIC: 3841 Surgical & Medical Instruments & Apparatus